Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.

Date publication

mai 2024

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, Ertl C, Tomsitz D, Tietze JK, Gutzmer R, Dabrowski E, Zimmer L, Gesierich A, Zierold S, French LE, Eigentler T, Amaral T, Heinzerling L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38652976

Résumé

Immune checkpoint inhibitors (ICI) induce adverse events (irAEs) that do not respond to steroids, i.e. steroid-refractory (sr) irAEs, and irAEs in which steroids cannot be tapered, i.e. steroid-dependent (sd) irAEs, in about 10% of cases. An evidence-based analysis of the effectiveness of second-line immunosuppressive agents with regard to irAE and tumor control is lacking.

Mots clés

Immune checkpoint inhibitors, Immune-related adverse events, Second-line immunosuppressants, Steroid-dependent, Steroid-refractory

Référence

Eur J Cancer. 2024 05;203:114028